Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleIEEE Spectrum

AI Models Fail Miserably at This One Easy Task: Telling Time

View original at spectrum.ieee.org
AI Models Fail Miserably at This One Easy Task: Telling Time <img src="https://spectrum.ieee.org/media-library/a-digitally-structured-tree-with-a-melting-clock-hanging-off-one-of-its-branches-the-concept-resembles-salvador-dali-s-persist.jpg?id=62053134&width=1200&height=800&coordinates=0%2C133%2C0%2C134" /><br /><br /…
Opening lines of the source · IEEE Spectrum · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • If a MLLM struggles with one facet of image analysis, this can cause a cascading effect that impacts other aspects of its image analysis

    80% confidence
  • We cannot take model performance for granted and extensive training and testing with varied inputs is necessary to ensure models remain robust against diverse real-world scenarios

    80% confidence
  • If the MLLMs made an error in recognizing the clock hands, this in turn resulted in greater spatial errors

    80% confidence
  • Reading the time is not as simple a task as it may seem, since the model must identify the clock hands, determine their orientations, and combine these observations to infer the correct time

    80% confidence
  • While such variations pose little difficulty for humans, models often fail at this task

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com
AI Models Fail Miserably at This One Easy Task: Telling Time — Source | Via News | Finance Via News